Home LiteratureArticle Details
PMID: 3028964 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial

Bacteriological data on a prospective multicenter study of the effect of two different regimens for selective decontamination in patients with acute leukaemia.

Infection ·Vol. 14 ·No. 6 ·1986-00-00 ·Pages 268-74

van der Waaij D, Gaus W, Krieger D, Linzenmeier G, Rozenberg-Arska M, de Vries-Hospers HG

Abstract

In this paper we described the results of bacteriological monitoring of oropharynx and stool samples from granulocytopenic patients with leukaemia who received oral infection prophylaxis with two different regimens for selective decontamination of the digestive tract. Patients were prospectively randomized either into a group receiving non-absorbable antimicrobial drugs for selective decontamination (polymyxin and neomycin: group A) or into a group receiving polymyxin and co-trimoxazole (group B). The oropharynx was, or became, free of gram-negative bacilli within one week of treatment in 94% and 90%, respectively, of the patients in group A and group B. The stool samples were, or became, negative after the same treatment interval in 91% and 80%, respectively, of the two patient groups. Antibiotic therapy during selective decontamination treatment significantly increased the incidence of positive cultures from the oropharynx and stools. The sensitivity of the gram-negative bacilli isolated during selective decontamination treatment to the drugs administered did not influence the average response to treatment. Both resistant and sensitive gram-negative bacteria appeared to disappear from the patients' samples, mostly within a week, without the need to adjust the selective decontamination treatment. Yeasts behaved in almost the same way as gram-negative bacilli. All patients received oral amphotericin B; some patients occasionally yielded oropharyngeal or faecal cultures which were positive for yeasts.

MeSH Terms
Acute Disease Amphotericin B/therapeutic use Bacterial Infections/prevention & control Drug Combinations/therapeutic use Drug Therapy, Combination Feces/microbiology Gram-Negative Bacteria/drug effects,isolation & purification Humans Leukemia/complications,microbiology Leukemia, Myeloid, Acute/complications,microbiology Neomycin/therapeutic use Oropharynx/microbiology Polymyxins/therapeutic use Prospective Studies Random Allocation Sulfamethoxazole/therapeutic use Trimethoprim/therapeutic use Trimethoprim, Sulfamethoxazole Drug Combination Yeasts/drug effects
Chemicals
Drug Combinations Polymyxins Amphotericin B Trimethoprim, Sulfamethoxazole Drug Combination Trimethoprim Neomycin Sulfamethoxazole
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
van der Waaij D
Gaus W
Krieger D
Linzenmeier G
Rozenberg-Arska M
de Vries-Hospers H G
References (5)
5 references, click to expand
  1. Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients.
    Antimicrob Agents Chemother. 1981 May;19(5):813-20 PMID: 7027923
  2. Prevention of infection in acute leukemia: a prospective randomized study on the efficacy of two different drug regimens for antimicrobial prophylaxis.
    Infection. 1986 Sep-Oct;14(5):226-32 PMID: 3491791
  3. Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients. Reduction of infections and effect on bacterial and fungal flora.
    Am J Med. 1983 Apr;74(4):599-607 PMID: 6837588
  4. Effect of systemic antimicrobial prophylaxis on microbial flora.
    Antimicrob Agents Chemother. 1982 Mar;21(3):367-72 PMID: 6285808
  5. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid.
    J Infect Dis. 1983 Apr;147(4):624-34 PMID: 6842003
Article Info
Journal
Infection
Abbr.
Infection
ISSN
0300-8126
Published
1986-00-00
Pages
268-74
Language
English
Region
Germany
NLM ID
0365307
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com